Opinion · Court of Appeals for the D.C. Circuit
Community Nutrition Institute, Laura A. Rogers v. Frank Young, Commissioner, Food and Drug Administration
Cmty. Nutrition Inst., Laura A. Rogers v. Frank Young, Comm’r, Food & Drug Admin., 818 F.2d 943 (Court of Appeals for the D.C. Circuit 1987)
- Type
- Opinion
- Court
- Court of Appeals for the D.C. Circuit
- Jurisdiction
- Federal
- Date
- 1987-05-15
- Topic
- bankruptcy
noting that “courts are to give far greater weight to the language actually used by the agency” in the past than to its present characterization of the rule | stating that the court should consider whether the agency action (1) "impose[s] any rights and obligations," or (2) "genuinely leaves the agency and its decisionmakers free to exercise discretion" | noting that “courts are to give far greater weight to the language actually used by the agency” than to the agency’s’ current characterization of that language | stating that the court should consider whether the agency action (1) “impose[s] any rights and obligations,” or (2) “genuinely leaves the agency and its decisionmakers free to exercise discretion” | describing the policy statement's “not inconsiderable benefits” of "informing the exercise of discretion by agents and officers in the field” | noting the “not inconsiderable benefits of apprising the regulated community of the agency’s inténtions” | warning of the “peril” of courts “transmogrifying] ... guidelines into binding norms” | "[A]n action level ... define[s] the level of contamination at which food will be deemed to be adulterated." (emphasis in original) | notice-and-comment required because the FDA, “by virtue of its own course of conduct”, gave action levels a “present, binding effect” | FDA could treat its rules as mere policy statements in the future, but “in order to do so, FDA must avoid giving action levels the kind of substantive significance that it now so plainly attaches to them” | “While mindful but suspicious of the agency’s own characterization, we follow the D.C. Circuit’s analysis ..., focusing primarily on whether the rule has binding effect on agency discretion or severely restricts it.” | “[W]e have ... found decisive the choice between the words ‘will’ and ‘may.’ ” | distinguishing between legislative and interpretative rules or statements of policy | distinguishing between legislative and interpretative rules or statements of policy | "The distinction between legislative rules and interpretative rules or policy statements has been described at various times as 'tenuous,' Chisholm v. FCC , 538 F.2d 349 , 393 (D.C. Cir.), cert. denied, 429 U.S. 890 , 97 S.Ct. 247 , 50 L.Ed.2d 173 (1976 | using the terms “interpretive rule” and “policy statement” interchangeably | use of “will” supports determination of legislative rule
Citator
- Cited by
- 50 opinions
Michael J. Ryan, Asst. U.S. Atty., with whom Joseph E. diGenova, U.S. Atty., Royce C. Lamberth, Craig Lawrence, Asst. U.S. Attys., Washington, D.C., Thomas Scarlett, Chief Counsel, Rockville, Md., and Michael M. Landa, Associate Chief Counsel for Enforcement, Food and Drug Admin., were on the brief for appellee. Patricia J. Kenney, Asst. U.S. Atty., Washington, D.C., Stephen D. Terman, Counsel, Food and Drug Admin., Rockville, Md., Richard K. Willard, Atty. Gen., Leonard Schaitman and John M. Rogers, Attorneys, Dept. of Justice, Washington, D.C., entered appearances for appellee.Page 945
Philip C. Olsson, Washington, D.C., was on the brief for amicus curiae in support of appellee, State of South Carolina, urging affirmance of the Dist. Court decision.
Opinion PER CURIAM.
Opinion concurring in part and dissenting in part filed by Circuit Judge STARR.
[2] CNI filed suit in federal district court, launching a three-pronged attack on FDA's action level for aflatoxins in corn: (1) in issuing the action level, FDA failed to comply with the rulemaking requirements of the Food, Drug and Cosmetic Act (FDC Act),see21 U.S.C. § 346; (2) the action level violated the Administrative Procedure Act because it constitutes a legislative rule issued without the requisite notice-and-comment procedures, see5 U.S.C. § 553; and (3) FDA's decision to permit adulterated corn to be blended with unadulterated corn to bring the total contamination within the action level violated the FDC Act. The District Court granted summary judgment in favor of FDA on each issue.
[3] In our initial opinion, we confined ourselves to CNI's first argument. We concluded that the FDC Act, by stating that FDA "shall promulgate regulations,"21 U.S.C. § 346, required that FDA issue formal regulations or "tolerances," rather than informal action levels. Having invalidated the action level on this ground, we concluded that CNI's APA argument was thus rendered moot and that the blending issue stood in need of reevaluation on remand. See757 F.2d 354(D.C. Cir. 1985).
[4] The Supreme Court reversed our decision, ___ U.S. ___,106 S.Ct. 2360,90 L.Ed.2d 959, holding that the FDC Act was not so clear as to preclude FDA's interpretation of the statute under which the agency could lawfully proceed by way of action levels.106 S.Ct. 2360(1986). Since the Court did not reach the APA or blending issues, it remanded the case to this court for "further proceedings consistent with [its] opinion."Id.at 2366. Thus, with the first issue resolved by the High Court, we must now address the still pending APA and blending issues.
[6] The distinction between legislative rules and interpretative rules or policy statements has been described at various times as "tenuous,"Chisholm v. FCC,538 F.2d 349,393(D.C. Cir.),cert. denied,429 U.S. 890,97 S.Ct. 247,50 L.Ed.2d 173(1976), "fuzzy,"Pacific Gas Electric Co. v.FPC,506 F.2d 33,38(D.C. Cir. 1974), "blurred," Saunders,Interpretative RulesWith Legislative Effect: An Analysis and a Proposal For PublicParticipation,1986 Duke L.J. 346, 352, and, perhaps most picturesquely, "enshrouded in considerable smog."Noel v.Chapman,508 F.2d 1023,1030(2d Cir.),cert. denied,423 U.S. 824,96 S.Ct. 37,46 L.Ed.2d 40(1975),quoted in American BusAssociation v. United States,627 F.2d 525,529(D.C. Cir. 1980).3As Professor Davis puts it, "the problem is baffling." 2 K. Davis, Administrative Law Treatise 32 (2d ed. 1979). By virtue of Congress' silence with respect to this matter, it has fallen to the courts to discern the line through the painstaking exercise of, hopefully, sound judgment.GuardianFederal Savings Loan Ass'n v. FSLIC,589 F.2d 658,667(D.C. Cir. 1978).
[7] Despite the difficulty of the terrain, prior cases do provide some useful guide-posts. In this circuit, we are particularly guided byAmerican Bus.There, in speaking for the court, Judge McGowan identified "two criteria" that courts have used in their efforts to fathom the interpretative/legislative distinction:
First, courts have said that, unless a pronouncement acts prospectively, it is a binding norm. Thus . . . a statement of policy may not have a present effect: "a `general statement of policy' is one that does not impose any rights and obligations". . . .
The second criterion is whether a purported policy statement genuinely leaves the agency and its decisionmakers free to exercise discretion.
[8]627 F.2d at 529(quotingTexaco v. FPC,412 F.2d 740,744(3d Cir. 1969)).4
[9] In conducting our analysis of these two criteria, we consider and give some, albeit "not overwhelming," deference to an agency's characterization of its statement.Brock v. CathedralBluffs Shale Oil Co.,796 F.2d 533,537(D.C. Cir. 1986).5As befits a principled exercise in interpretation, courts are to give far greater weight to the language actually used by the agency; we have, for example, found decisive the choice between the words "will" and "may."Compare American Bus,627 F.2d at 532(use of "will" indicates statement is in fact a binding norm)with Guardian Federal,589 F.2d at 666(use of "may" indicates statement is a "general statement of policy").
[10] Applying these principles to the case at hand, we are persuaded that the FDA action levels are legislative rules and thus subject to the notice-and-comment requirements of section 553. While FDAPage 947now characterizes the action levels as policy statements,see,e.g.,Supplemental Brief for Appellee at 7 ("In sum, action levels do not bind courts, food producers or FDA."), a variety of factors, when considered in light of the criteria set out inAmerican Bus,indicate otherwise.
[11]First.The language employed by FDA in creating and describing action levels suggests that those levels both have a present effect and are binding. Specifically, the agency's regulations on action levels explain an action level in the following way:
[A]n action level for an added poisonous or deleterious substance . . . may be established to define the level of contamination at which foodwillbe deemed to be adulterated.An action level mayprohibit any detectable amount of substance infood.
[12]21 C.F.R. § 109.4(1986) (emphasis added).6This language, speaking as it does of an action level "defin[ing]" the acceptable level and "prohibit[ing]" substances, clearly reflects an interpretation of action levels as presently binding norms.7This type of mandatory, definitive language is a powerful, even potentially dispositive, factor suggesting that action levels are substantive rules.Cf. Cathedral Bluffs,796 F.2d at 538. Moreover, the regulations provide that an action level may appropriately be established whenever there exist the same conditions required to establish a formal tolerance, if, in addition, the "appropriateness" of the tolerance may change in the near future because, for example, of technological changes.21 C.F.R. § 109.6(c);see also id.§ 109.6(b) (requirements for establishing a tolerance).8
[13]Second.This view of action levels — as having a present, binding effect — is confirmed by the fact that FDA considers it necessary for food producers to secureexceptionsto the action levels. A specific regulatory provision allows FDA to "exempt from regulatory action and permit the marketing of any food that is unlawfully contaminated with a poisonous or deleterious substance" if certain conditions exist.Id.§ 109.8(a). This language implies that in the absence of an exemption, food with aflatoxin contamination over the action level is "unlawful." This putatively unlawful status can derive only from the action level, which, again, indicates that the action level is a presently binding norm. If, as the agency would have it, action levels did indeed "not bind courts, food producers or FDA," Supplemental Brief for Appellee at 7, it would scarcely be necessary to require that "exceptions" be obtained.
[14]Third.On several occasions, in authorizing blending of adulterated with unadulterated corn,see infraPart II, the FDA has made statements indicating that action levels establish a binding form. For example, in a telegram to the Commissioner of the South Carolina Department of Agriculture,Page 948in which it indicated its approval of a blending plan, the FDA stated that "[a]ny shipments made independent of this planwould,if found to exceed the 20 ppb level,be consideredadulterated and subject to condemnation." Joint Appendix (J.A.) at 112 (emphasis added). But we need not resort to informal communications,cf. Ciba-Geigy Corp. v. EPA,801 F.2d 430(D.C. Cir. 1986), where precision of draftsmanship may understandably be wanting. For, in a formal notice published in the Federal Register of a decision to permit blending and interstate shipment, FDA wrote:
Any food that contains aflatoxin in excess of 20 ppb . . .is considered by FDA to be adulteratedunder section 402(a)(1) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. § 342(a)(1)), andthereforemay not be shipped in interstate commerce.
[15]46 Fed.Reg. 7447(1981) (emphasis added),reprinted inJ.A. at 49. Both statements, one informal and the other elaborately formal, indicate that, when judged under theAmerican Buscriteria, action levels constitute substantive rules. The agency's own words strongly suggest that action levels are not musings about what the FDA might do in the future but rather that they set a precise level of aflatoxin contamination that FDA has presently deemed permissible. Action levels inform food producers what this level is; indeed, that is their very purpose.
[16] We are not unmindful that in a suit to enjoin shipment of allegedly contaminated corn, it appears that FDA would be obliged to prove that the corn is "adulterated," within the meaning of the FDC Act, rather than merely prove non-compliance with the action level.See United States v. Boston Farm Center, Inc.,590 F.2d 149,151(5th Cir. 1979).9The action level thus does not bind food producers in the sense that producers are automatically subject to enforcement proceedings for violating the action level. This factor, accordingly, points in favor of the agency's characterization. But the fact that action levels do not completely bind food producers as would a more classic legislative rule (where the only issue before the court would be if the agency rule were in fact violated) is not determinative of the issue. For here, we are convinced that FDA has bound itself. As FDA conceded at oral argument, it would be daunting indeed to try to convince a court that the agency could appropriately prosecute a producer for shipping corn with less than 20 ppb aflatoxin. And this type of cabining of an agency's prosecutorial discretion can in fact rise to the level of a substantive, legislative rule.Cf. Nader v. CAB,657 F.2d 453(D.C. Cir. 1981);Guardian Federal,589 F.2d at 666-67("If it appears that a so-called policy statement is in purpose or likely effect one thatnarrowly limits administrative discretion,it will be taken for what it is — a binding rule of substantive law.") (emphasis added). That is exactly what has happened here.
[17] In sum, consideration of a variety of factors leads us to conclude that the FDA's action levels are not within the section 553(b)(3)(A) exception to notice-and-comment requirements.10Since all agree thatPage 949those procedures were not followed, the action level at issue here cannot stand.
[18] We pause to observe that nothing in our decision today generally precludes FDA from proceeding by way of informal action levels. The Supreme Court has, of course, decided that such a course is permissible under the FDC Act. Our limited holding is that the current action levels are treated as substantive rules by FDA and, as such, can only be permitted if notice-and-comment procedures are employed. If it so chooses, FDA could proceed by action levels that are pure policy statements. But in order to do so, FDA must avoid giving action levels the kind of substantive significance that it now so plainly attaches to them.
[19] We add one additional caveat. Our holding today in no way indicates that agencies develop written guidelines to aid their exercise of discretion only at the peril of having a court transmogrify those guidelines into binding norms. We recognize that such guidelines have the not inconsiderable benefits of apprising the regulated community of the agency's intentions as well as informing the exercise of discretion by agents and officers in the field. It is beyond question that many such statements are non-binding in nature and would thus be characterized by a court as interpretative rules or policy statements. We are persuaded that courts will appropriately reach an opposite conclusion only where, as here, theagencyitself has given its rules substantive effect.
[20] In sum, our holding today is narrow. We conclude that in the circumstances of this case, FDA by virtue of its own course of conduct has chosen to limit its discretion and promulgated action levels which it gives a present, binding effect. Having accorded such substantive significance to action levels, FDA is compelled by the APA to utilize notice-and-comment procedures in promulgating them.
[22] CNI contends that this blending practice causes the final product to be "adulterated" within the meaning of21 U.S.C. § 342(a)(2)(A). This section reads, in relevant part, as follows:
A food shall be deemed to be adulterated — . . . if it bears or contains any added poisonous or added deleterious substance . . . which is unsafe within the meaning of section 346 of this title.
[23] Section 346, in turn, states that
[a]ny poisonous or deleterious substance added to any food, except where such substance . . . cannot be avoided . . . shall be deemed to be unsafe for purposes of the application of clause (2)(A) of section 342(a).
[24]21 U.S.C. § 346. Theintentionalblending of contaminated corn obviously cannot in reason be considered unavoidable. Surely there can be little doubt that blended corn therefore stands branded as "adulterated" for purposes of the FDC Act; indeed, in its initial brief FDA conceded as much:
The Government does not dispute [CNI's] contention that use of an adulterated feed as an ingredient in another feed causes the finished (blended) feed to be adulterated.
[25] Brief for Appellee at 36. But as FDA goes on to point out, a conclusion that a particular food product is "adulterated," in the abstract, means little other than that FDAPage 950could choose to initiate enforcement proceedings. CNI does not, and could not, point to any provision in the FDC Act requiring FDA to initiate enforcement action against every food falling within the Act's definition of "adulterated." Rather, the Act makes clear that these enforcement decisions are vested, as they traditionally are, with the agency. Section 336, for example, expressly recognizes that FDA need not "report for prosecution, or for the institution of libel or injunction proceedings, minor violations of this [Act]."21 U.S.C. § 336.
[26] Upon analysis, therefore, the gravamen of CNI's complaint is that FDA failed to initiate enforcement proceedings. But as the Supreme Court held inHeckler v. Chaney,470 U.S. 821,105 S.Ct. 1649,84 L.Ed.2d 714(1985), FDA enjoys complete discretion not to employ the enforcement provisions of the FDC Act, and those decisions are not subject to judicial review. As this court recently concluded, the "provisions [of the FDC Act] authorize, but do not compel the FDA to undertake enforcement activity; they `commit complete discretion to the [FDA] to decide how and when they should be exercised.'"Schering Corp. v. Heckler,779 F.2d 683,686(D.C. Cir. 1985) (quotingHeckler v. Chaney,105 S.Ct. at 1658). In light of this principle, CNI's arguments on the blending issue must fall.
[28]It is so ordered.
The critical distinction between a substantive rule and a general statement of policy is the different practical effect that these two types of pronouncements have in subsequent administrative proceedings. . . . A properly adopted substantive rule establishes a standard of conduct which has the force of law.
[31]506 F.2d 33,38(D.C. Cir. 1974). ThePacific Gas-enunciated factor — whether the pronouncement has the force of law in subsequent proceedings — should be deemed determinative of the issue. Because there is no doubt that the agency pronouncements at issue here have no such effect, I respectfully dissent from section I of the panel opinion.
[33] Before such rules are sanctioned one would think that they should be carefully crafted, with the "underlying polic[ies] embodied in the rule" recognized, openly discussed, and deliberately weighed. To return to basic civics for a moment, statutes passed by Congress have been refined in this manner by the very nature of the legislative process. Bills are considered by committees, hearings are held, debate is conducted, compromises are reached, and votes are taken. And all this is carried on in a bicameral legislative body with the final result presented to the President forPage 951his approval or rejection.See INS v. Chadha,462 U.S. 919,103 S.Ct. 2764,77 L.Ed.2d 317(1983). A statute therefore possesses important attributes justifying placement of the coercive power of the state behind a particular policy framed in accordance with the process ordained at the Founding.
[34] In the modern administrative state, many "laws" emanate not from Congress but from administrative agencies, inasmuch as Congress has seen fit to vest broad rulemaking power in the executive branch, including independent agencies.See Synar v.United States,626 F.Supp. 1374,1383-84(D.D.C.) (three judge court),aff'd,___ U.S. ___,106 S.Ct. 3181,92 L.Ed.2d 583(1986); K. DavisAdministrative Law Treatise§ 3.8 (1982 Supp.);cf. Ticor Title Insurance Co. v. FTC,814 F.2d 731,732(D.C. Cir. 1987) (dismissing on procedural grounds a challenge to the delegation of law enforcement powers to an independent agency). This rulemaking power is obviously cabined by whatever requirements may exist in the particular statute delegating rulemaking authority, a subject which we treated in our initial decision in this case.See757 F.2d 354(D.C. Cir. 1985). But Congress has also provided in the APA for certain procedural protections before that which achieves the lofty status of "law" is promulgated by an agency acting in its Congressionally authorized lawmaking capacity. Chief among these protections are the notice-and-comment requirements laid down in the familiar provision of5 U.S.C. § 553. In a sense, notice-and-comment procedures serve as a Congressionally mandated proxy for the procedures which Congress itself employs in fashioning its "rules," as it were, thereby insuring that agency "rules" are also carefully crafted (with democratic values served by public participation) and developed only after assessment of relevant considerations. It is thus, in theory, important for APA procedures to be followed before an agency pronouncement is deemed a binding legislative rule not merely because the APA says so, but because is saying so the APA is protecting a free people from the danger of coercive state power undergirding pronouncements that lack the essential attributes of deliberativeness present in statutes. Because of the value inhering in such procedures, it is well-established that "`only reluctantly should courts recognize exceptions therefrom.'"American Bus Association v. United States,627 F.2d 525,528(D.C. Cir. 1980) (quotingHumana of South Carolina v. Califano,590 F.2d 1070,1082(D.C. Cir. 1978)).
[35] Nonetheless, in crafting the APA, Congress directed that courts should recognize certain exceptions to the statute's notice-and-comment requirements. Specifically, Congress recognized that not all agency pronouncements, even those of considerable moment, rise to the dignity of law. Thus, the APA excepts, as the panel opinion recounts, interpretative rules and general statements of policy from the general notice-and-comment requirements. While it is no doubt true, and indeed is frequently recognized, that such agency pronouncements may have a direct effect on the regulated community, and may even be judicially reviewable,see, e.g., AFL-CIO v. Donovan,757 F.2d 330,341-43(D.C. Cir. 1985);cf. Abbott Laboratories v. Gardner,387 U.S. 136,87 S.Ct. 1507,18 L.Ed.2d 681(1967), these pronouncements still lack the dignity of "law." Before that status can be achieved, the agency must run its policies through the notice-and-comment gantlet. Perhaps in part because the agency here has avoided testing its pronouncements in this way, it must in any future proceeding defend and justify its chosen standard in the face of a challenge to that standard.Cf. United Statesv. Boston Farm Center, Inc.,590 F.2d 149,151(5th Cir. 1979).
[37] We should reembrace ourPacific Gastest as the determinative factor in analyzing whether a particular pronouncement is legislative or interpretative in nature. If the pronouncement has the force of law in future proceedings, it is a legislative rule. Unless that critical feature is present, however, the agency statement should be considered to be a lower form of pronouncement, a "non-law" as it were, or in APA terms an "interpretative rule" or "general statement of policy." The correct measure of a pronouncement's force in subsequent proceedings is a practical one: must the agency merely show that the pronouncement has been violated or must the agency, if its hand is called, show that the pronouncement itself is justified in light of the underlying statute and the facts.
[38] Application of this test can readily be illustrated by the case at hand.2Action levels offer guidance to the regulated community with respect to what products FDA deems adulterated within the meaning of the FDC Act. But in an enforcement proceeding in which FDA seeks either to impose sanctions for shipment of an adulterated product or to enjoin shipment of an adulterated product, the agency must prove the product is "adulterated." That is, FDA cannot merely show that the product at issue fails to comply with the action level.See Boston FarmCenter,590 F.2d at 151. Rather, FDA must offer scientific or other probative evidence to support its contention that the product is adulterated. Thus, the action level does not have the force of law in the subsequent proceeding. Indeed, it has no "force" at all.
[39] Let me quickly observe that I am not encouraging rebellion and sedition within the circuit. While the law has certainly evolved sincePacific Gas,at no point has this court disavowed that decision.3Quite to the contrary, the leading case sincePacific Gas, American Bus,expressly embraced the earlier decision.SeePage 953627 F.2d at 529. Moreover, post-American Busdecisions grappling with the legislative rule-interpretative rule distinction have often emphasized thePacific Gasfactor. Just the other day, for example, Judge Bork, in writing for the court inThe NationalLatino Media Coalition v. FCC,816 F.2d 785,788(D.C. Cir. 1987), emphasized that "an interpretative rule does not have the force of law and is not binding upon anyone" in holding that the agency pronouncements at issue there were not legislative rules and thus not subject to the APA's notice-and-comment requirements. To my eye, this represents an application, albeit not explicit, ofPacific Gas.Thus, I viewPacific Gasas not only "good" law, in the sense that it has never been overruled, but can discern in our precedents examples, including very fresh ones, of its being heartily applied. I would therefore urge that the "force of law" factor fromPacific Gasbe explicitly recognized anew as the polestar guiding the legislative-interpretative determination. Such a modest step would not only be faithful to fundamental principles informing the nature of legislative rules but would have the happy practical consequence of bringing clarity to a troubled area.
[40] While I thus view this step as warranted, I recognize a potential danger lurking in the embrace of a single-factor,Pacific Gastest. Agencies may yield to temptation and seek to shield their regulations from the scrutiny occasioned by notice-and-comment procedures, choosing instead to cast would-be regulations as interpretative rules. The rule would still, of course, be subject to scrutiny in a subsequent proceeding, but this fact may be of little comfort to prospective commentors, given the deference accorded agency views in any such proceedings.See generally Chevron U.S.A. Inc. v. NRDC,467 U.S. 837,104 S.Ct. 2778,81 L.Ed.2d 694(1984). But upon analysis, the danger is more theoretical than real. Indeed, Congress not atypically provides agencies with a direct command to promulgate regulations,cf., e.g., Industrial UnionDepartment, AFLCIO v. American Petroleum Institute,448 U.S. 607,100 S.Ct. 2844,65 L.Ed.2d 1010(1980), thereby imposing a duty that would not be satisfied with issuance of an humble interpretative rule. In this case, of course, the Supreme Court has now ruled that FDA isnotrequired by the organic statute to issue formal regulations, but can instead proceed by way of informal action levels. ___ U.S. ___,106 S.Ct. 2360,90 L.Ed.2d 959(1986). But if Congress prefers a traditional model of command to the agencies to issue regulations, it can embrace that model through legislation, informed by the need, reiterated by the Supreme Court in this very case, to avoid dangling participles and other forms of that omnipresent occupational hazard of the draftsman's workshop, ambiguity.But see INS v.Cardoza-Fonseca,___ U.S. ___,107 S.Ct. 1207,94 L.Ed.2d 434(1987);Board of Governors v. Dimension Financial Corp.,474 U.S. 361,106 S.Ct. 681,88 L.Ed.2d 691(1986). BecausePacificGas,and the basic principles upon which it stands, points the way to a quite different result than that reached by my colleagues, I am constrained to dissent in part.
- Aflatoxins are by-products of certain common molds that grow on various crops, including corn. ↩
- The APA defines "rule" as "the whole or a part of an agency statement of general or particular applicability and future effect designed to implement, interpret, or prescribe law or policy. . . ."5 U.S.C. § 551(4). FDA does not dispute that its action levels are indeed "rules." The notice-and-comment requirements of section 553 are thus unquestionably triggered and the only question before us is whether one of the statutory exceptions to notice and comment is applicable. ↩
- See also Brock v. Cathedral Bluffs Shale Oil Co.,796 F.2d 533,536-37(D.C. Cir. 1986) ("[T]here is no axiom to distinguish between a regulation and general statements of policy."). ↩
- The first criterion fromAmerican Buscould be read as facially inconsistent with the APA. Specifically, criterion one appears to indicate that interpretative rules must be solely prospective: "[C]ourts have said that, unless a pronouncement acts prospectively, it is a binding norm."627 F.2d at 529. Since under the APA, interpretative rules can be developed and offered aspresentindications of the agency's enforcement policy, this "present-is-legislative" reading ofAmerican Buswould create a conflict with the statutory definition. In our view, however, criterion one fromAmerican Busis addressed to the binding effect of the agency pronouncement; if a statement has a present-day binding effect, it is legislative. Mere pronouncements of what the agency intends, whether for the present or for the future, which do not have a binding effect, are properly classified as interpretative rules. Thus, it is the binding effect, not the timing, which is the essence of criterion one. ↩
- As now-Justice Scalia put it when writing for this court: "[T]here is deference and there is deference — and the degree accorded to the agency on a point such as this is not overwhelming."Cathedral Bluffs,796 F.2d at 537. ↩
- The conditional "may" in this provision refers only to the agency's discretion in deciding whether to establish an action level. It does not suggest that, once established, an action level is non-binding. Rather, with respect to binding effect, the regulation speaks in non-conditional terms. ↩
- See also Action Levels for Poisonous or DeleteriousSubstances in Human Food and Animal Feed(FDA Publication 1980) ("Action levels and tolerances represent limits at or above which FDAwill takelegal action to remove adulterated products from the market.") (emphasis added),reprinted inJoint Appendix (J.A.) at 76, 77. ↩
- The specific action level for aflatoxin in corn was published in theFederal Register.InCathedral Bluffs,this court indicated that such publication did not necessarily suggest that "the matter publishedwasmeant to be a regulation, since the APA requires general statements of policy to be published as well."796 F.2d at 539(emphasis in original). Rather, theCathedral Bluffscourt indicated that the "real dividing point between regulations and general statements of policy is publication in the Code of Federal Regulations."Id.This factor, among others, led the court to conclude that the pronouncement at issue there was a general statement of policy. In our case, however, the line cannot be so simply drawn. While the specific action level itself was not published in the Code of Federal Regulations, FDA did publish in the C.F.R. regulations authorizing establishment of action levels which, as noted above, indicate that action levels are to have a binding effect. Thus, we deal with a mixedFederal Register-C.F.R. publication, and accordingly find ourselves unable to divine persuasive indications, one way or another, from what may be called the "publication factor." ↩
- Boston Farm Centercould be read to indicate that the Fifth Circuit viewed action levels as mere general statements of policy. In reviewing the Government's argument that a court should defer to the action level as positively indicating a violation of the Act, theBoston Farm Centercourt noted that "[t]he deference principle is less compelling when the agency threshold is a matter of prosecutorial discretion instead of rule-making."590 F.2d at 149.But see United States v. EwigBros.,502 F.2d 715,725(7th Cir. 1974) (An action level is "meant to operate more like a rule of general applicability than a mere prediction of how the agency would choose to exercise its prosecutorial discretion."),cert. denied,420 U.S. 945,95 S.Ct. 1324,43 L.Ed.2d 423(1975). We may well prefer the Seventh Circuit's characterization, but neither court was addressing the issue before us: whether action levels are within the interpretative rules/general statements of policy exception to APA notice-and-comment requirements. Thus, these casual characterizations are of limited help in our inquiry. ↩
- Our conclusion is buttressed by the Supreme Court's opinion in this case, which could be read to reflect an understanding of the action levels as substantive rules. Specifically, the Court described action levels in the following terms: "In setting an action level, the FDA essentially assures food producers that it ordinarily will not enforce the general adulteration provisions of the Act against them."106 S.Ct. at 2363. This characterization of the action levels as an agency assurance is consistent with our holding that the action levels are substantive rules subject to notice-and-comment procedures. ↩
- In addition, the difficulty can be seen in attempts by courts to quite understandably make sense of this area by seeking simple, easily-applied rules. InBrock v. Cathedral Bluffs ShaleOil Co.,796 F.2d 533,539(D.C. Cir. 1986), now-Justice Scalia intimates that "[t]he real dividing point between regulations and general statements of policy is publication in the Code of Federal Regulations." Such an approach would certainly be simple, if arguably inconsistent with the notion that the deference entitled to an agency's own characterizations of its statements is "not overwhelming."Id.,at 537. I prefer thePacific Gasapproach, which has a much firmer rooting in the core principles at issue. ↩
- I recognize that in many ways, nothing can be "readily" demonstrated by the case at hand; action levels, as the FDA has fashioned them, are a rather curious hybrid. Under a functionalist analysis, this form of agency action comes tantalizingly close to a substantive rule. I find particularly compelling the fact that FDA considers it necessary to grant "exceptions" to its action levels.See21 C.F.R. § 109.8 (1986). Thus, I must confess in candor that I view the majority's approach not only as faithful to our circuit's more recent pronouncements, but as buttressed by common sense. ↩
- What seems to have taken place as the law has evolved (and arguably become obfuscated) is that thePacific Gasfactor has been consigned to a supporting role, as one aspect of what seems to be a multi-factor test. ↩